patent.fyi
Applications  /  US 2026/0355133
United States Patent Application Publication

US 2026/0355133 A1

Published
Nov 12, 2026
Filed
Oct 14, 2025
Earliest date on the face
Dec 20, 2018
Classification
A61K 31/165
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Synthetic cannabinoid source

What ifWhat if the cannabinoid came from chemical synthesis and was administered with a TRPV1 antagonist?
Claim language“at least one marijuana-derived cannabinoid”

Chemical synthesis supplies purified cannabidiol without plant extraction. Chromatography measures cannabidiol content and related impurities before formulation for administration with the TRPV1 antagonist.

1.1Topical TRPV1 activation

What ifWhat if topical capsaicin supplied the TRPV1-directed step by activating the channel?
Claim language“at least one TRPV1 antagonist”

A cream delivers capsaicin to intact skin, where it activates TRPV1 channels on cutaneous sensory nerve endings. Continued exposure reduces the responsiveness of those endings to subsequent stimulation.

1.1Dopamine receptor blockade

What ifWhat if a dopamine D2 receptor antagonist controlled vomiting through a separate receptor pathway?
Claim language“at least one TRPV1 antagonist”

A parenteral formulation delivers haloperidol during the acute episode. Haloperidol blocks D2 receptors involved in emetic signaling, and an electrocardiogram measures the corrected QT interval.

1.1Fluid and electrolyte replacement

What ifWhat if intravenous fluid and electrolyte replacement addressed the acute episode without the drug pair?
Claim language“at least one marijuana-derived cannabinoid in combination with”

An intravenous isotonic crystalloid restores circulating volume depleted by repeated vomiting. Serum electrolyte measurements guide potassium and magnesium replacement.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Paired exposure in veterinary sensory assays

A veterinary pharmacology assay exposes cultured canine sensory neurons to a marijuana-derived cannabinoid and a TRPV1 antagonist in the same well. A four-condition plate layout includes vehicle, cannabinoid alone, antagonist alone, and the pair. After exposure, a capsaicin challenge evokes a calcium signal, and fluorescence measurements quantify the response in each condition.

Component substitution

Synthetic delta-9-tetrahydrocannabinol as the cannabinoid

Chemically synthesized delta-9-tetrahydrocannabinol replaces the marijuana-derived cannabinoid in a paired-exposure assay. A liquid handler dispenses the synthetic compound and a TRPV1 antagonist from separate stock solutions into wells containing sensory neurons. The assay holds the carrier concentration constant across wells and records capsaicin-evoked calcium signals after exposure.

Parameter or scale variation

Staggered exposure in a perfusion chamber

A perfusion chamber containing cultured sensory neurons connects to separate reservoirs for a marijuana-derived cannabinoid, a TRPV1 antagonist, and carrier solution. The antagonist enters the chamber 0, 5, or 15 minutes before the cannabinoid and remains present during cannabinoid exposure. A 60-second capsaicin pulse follows 10 minutes of joint exposure, and a camera records calcium fluorescence at 2 frames per second.

Separate oral and topical delivery routes

A clinical study uses an oral preparation containing a marijuana-derived cannabinoid and a separate topical preparation containing a TRPV1 antagonist. Staff apply the topical preparation over a measured 25-square-centimeter area of intact abdominal skin and record the application and oral administration times separately. Symptom assessments occur at baseline and at 30, 60, and 120 minutes after oral administration.

Combination with existing systems

Paired administration with electronic medication records

An electronic medication administration record links separate orders for a marijuana-derived cannabinoid and a TRPV1 antagonist under a shared study visit identifier. Barcode scanning matches each preparation to its order and records the lot number, route, and actual administration time. The record links those entries to symptom assessments from the same visit so reviewers can align each assessment with both administrations.

Automated or data-driven variant

Automated calcium imaging of paired exposures

A liquid-handling robot dispenses a marijuana-derived cannabinoid and a TRPV1 antagonist across a concentration matrix in a plate containing cultured sensory neurons. An imaging system records baseline calcium fluorescence and captures the response after an automated capsaicin addition. Software calculates the peak fractional fluorescence change for each well and exports the result with both concentrations and the well identifier.

Specific version of a part

Separate oral dose units

An oral soft capsule contains a measured quantity of plant-derived cannabidiol dissolved in a lipid vehicle. A separate immediate-release tablet contains a small-molecule TRPV1 antagonist, and the dosing protocol specifies administration of both units at the same visit.

Combined oral capsule

A hard capsule contains two populations of granules, one carrying plant-derived cannabidiol and the other carrying a small-molecule TRPV1 antagonist. Chromatographic assays measure the amount of each active ingredient, and a dissolution test measures release from the finished capsule.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2006/0281718 A1
Published
Dec 14, 2006
Filed
May 12, 2006
Class
A61K 31/60
Document BUS 2009/0312433 A1
Published
Dec 17, 2009
Filed
Aug 28, 2009
Class
A61K 31/16
Claim 1
Document A
Document B
1.1administering to a patient in need thereof, at least one marijuana-derived cannabinoid in combination with a therapeutically effective amount of at least one TRPV1 antagonist.
In this study rats were first treated with vehicle (Oraplus/5% Tween 80) or a TRPV1 antagonist (Compound A; 3 mg/kg, p.o.). Following a 120 min period, separate groups of rats were then administered vehicle (Oraplus/5% Tween 80) or acetaminophen (300 mg/kg, p.o.).
A · US 2006/0281718 A1 · ¶ 310
In this study rats were first treated with vehicle (Oraplus/5% Tween 80) or a TRPV1 antagonist (Compound A; 3 mg/kg, p.o.). Following a 120 min period, separate groups of rats were then administered vehicle (Oraplus/5% Tween 80) or acetaminophen (300 mg/kg, p.o.).
B · US 2009/0312433 A1 · ¶ 319

An empty cell means only that no passage was reproduced there.

Statements in these documents
Since this effect may be considered an adverse event in humans, and may limit the amount of a VR1 antagonist that can be administered, preventing and/or reversing a temperature increase induced by treatment with a VR1 antagonist is important.
A · US 2006/0281718 A1 · ¶ 5
This paradigm causes receptor activation induced desensitization of the primary sensory nerve—such reduction in sensory nerve activity in vivo makes subjects less sensitive to subsequent painful stimuli.
A · US 2006/0281718 A1 · ¶ 4
Since this effect may be considered an adverse event in humans, and may limit the amount of a VR1 antagonist that can be administered, preventing and/or reversing a temperature increase induced by treatment with a VR1 antagonist is important.
B · US 2009/0312433 A1 · ¶ 5
This paradigm causes receptor activation induced desensitization of the primary sensory nerve—such reduction in sensory nerve activity in vivo makes subjects less sensitive to subsequent painful stimuli.
B · US 2009/0312433 A1 · ¶ 4
Cite aspatent.fyi, US 2026/0355133 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355133/, SHA-256 b94f6cfb195bc727e455852eddd9aac3d457cbbf568e5e36f7aa1f1070b971a6
First published
Permanent addresshttps://patent.fyi/US20260355133/
Content fingerprint (SHA-256)b94f6cfb195bc727e455852eddd9aac3d457cbbf568e5e36f7aa1f1070b971a6
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi